Published in final edited form as:

Am J Trop Med Hyg. 2007 December ; 77(6 Suppl): 79–87.

Vivax malaria:

neglected and not benign

Ric N Price^{1,2}, Emiliana Tjitra³, Carlos A Guerra^{4,5}, Shunmay Yeung, Nicholas J White^{2,6}, and Nicholas M Anstey¹

¹International Health Program, Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia ²Centre for Vaccinology & Tropical Medicine, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford, UK ³National Institute of Health Research and Development, Ministry of Health, Jakarta, Indonesia ⁴Spatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, Tinbergen Building, South Parks Road, Oxford, OX1 3PS, UK ⁵Malaria Public Health & Epidemiology Group, Centre for Geographic Medicine, KEMRI-Wellcome Trust-Collaborative Programme, Kenyatta National Hospital Grounds, P.O. Box 43640-00100 Nairobi, Kenya ⁶Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand

Abstract

Plasmodium vivax threatens almost 40% of the world's population, resulting in 132 - 391 million clinical infections each year. Most of these cases originate from South East Asia and the Western Pacific, although a significant number also occur in Africa and South America. Although often regarded as causing a benign and self-limiting infection, there is increasing evidence that the overall burden, economic impact and severity of disease from *P. vivax* have been underestimated. Malaria control strategies have had limited success and are confounded by the lack of access to reliable diagnosis, emergence of multidrug resistant isolates and the parasite's ability to transmit early in the course of disease and relapse from dormant liver stages at varying time intervals after the initial infection. Progress in reducing the burden of disease will require improved access to reliable diagnosis and effective treatment of both blood-stage and latent parasites, and more detailed characterization of the epidemiology, morbidity and economic impact of vivax malaria. Without these, vivax malaria will continue to be neglected by ministries of health, policy makers, researchers and funding bodies.

INTRODUCTION

The last decade has brought fresh impetus to the fight against malaria, driven by a growing appreciation of the humanitarian and economic magnitude of the problem and access to new funding sources 1. For the most part this resurgence of interest has focused on infections with *Plasmodium falciparum*, which is associated with the greatest mortality and, in sub-Saharan Africa, intensity of transmission. In contrast *P. vivax*, the other major species infecting humans, is usually considered a "benign" infection receiving lower priority from researchers, policy makers and funding bodies. Although the emphasis on *P. falciparum* is appropriate, the burden of vivax malaria should not be under appreciated and exacts a significant toll on almost 40% of the world's population. In this paper we examine new

Correspondence to: Dr Ric Price Menzies School of Health Research, PO Box 41096, Casuarina, Darwin, NT 0811 Australia; email: rnp@menzies.edu.au, Tel: (61) 8 8922 8197, Fax: (61) 8 8922 8429.

No conflict of interests declared.

evidence highlighting the magnitude of this burden and discuss major challenges to achieving a successful control strategy.

Epidemiology

Using national statistics reported by regional offices of the World Health Organization, the 1999 World Health Report estimated that there are between 72 to 80 million cases of malaria due to *P. vivax* each year with the greatest burden observed in South and East Asia (52%), Eastern Mediterranean (15%) and South America (13%)². Recently these statistics have been challenged by an analysis using a combination of geographic information systems, malaria epidemiology, historical maps and information on population densities, environment, and vector limits³. Revised estimates of the global malaria burden were found to be up to 2.5 fold higher than that derived from national statistics⁴. In preliminary work, Hay and colleagues also found that non-falciparum malaria, predominantly *P. vivax*, accounts for 25-40% of the global malaria burden with between 132 - 391 million cases per year; table 1. When the population density of areas endemic for *P. vivax* is taken into consideration, the number of people at risk of infection reaches 2.6 billion, slightly greater than that for *P. falciparum*³. Although the debate over methodologies continues^{5, 6}, it is likely that the true burden of vivax malaria has been grossly underappreciated and is probably in the region of a quarter of a billion clinical cases a year.

In south and south east Asia, where the majority of vivax malaria occurs, *P. vivax* accounts for up to 50% of malaria cases with prevalence rates between 1-6% of the population^{7, 8, 9}. The proportional burden of vivax is even greater in Central and South America, reaching 71-81% of all malaria cases¹⁰. In eastern and southern Africa only 5% of malaria infections are attributable to *P. vivax*, although this still accounts for between 6-15 million cases per year². The emergence of chloroquine-resistant *P. falciparum* has tended to reduce the proportion of malaria cases due to *P. vivax*¹¹; nevertheless the absolute numbers of *P. vivax* remain high. Conversely, where successful malaria control strategies have been employed the ratio of *P. falciparum* to *P. vivax* infections has fallen¹².

In most areas the burden of disease is greatest in young children and infants with immunity usually developing by 10-15 years of age¹³. In a longitudinal study from Thailand, incidence rates varied from over 800 per 100 person -years in children under 5 yrs to 200 per 100 person years in older adults. In these low transmission settings premunition and asymptomatic carriage occur¹⁴, although overall 82% of patients with *P. vivax* parasitaemia were still found to be symptomatic⁷. Extrapolating this figure to estimated total number *P. vivax* infections presented in table 1, suggests that there are between 106 and 313 million clinical cases of vivax malaria each year.

Pathobiology

Compared to *P. falciparum*, *P. vivax* has a slightly longer incubation period (12 days to several months), a similar erythrocytic cycle (42-48 hours) and produces fewer merozoites per schizont¹⁵. It is generally believed that *P. vivax* merozoites require a single cell receptor, the Duffy antigen, to invade host erythrocytes. Humans lacking this antigen are not susceptible to infection, explaining why *P. vivax* is largely absent from West Africa, a highly malarious region where the Duffy negative blood group is ubiquitous¹⁶. Recently this paradigm has been challenged by observations in east Africa, demonstrating *P. vivax* transmission in a population found to be Duffy antigen negative, although further studies are needed to elucidate the epidemiology¹⁷. *P. vivax* is further limited by its apparent preference for invading young red cells, whereas *P. falciparum* invades a broader range of erythrocyte ages¹⁸. This selective preference for red cell invasion is an important factor limiting the growth of *P. vivax* both *in vitro* and *in vivo*. The latter was noted over 100 years

ago by Ross who commented upon the lower levels of parasitaemia observed in febrile patients with benign tertian malaria (*P. vivax*) compared to those with malignant tertian (*P. falciparum*)¹⁹. *P. vivax* is capable of inducing fever at levels of parasitemia lower than those causing fever in *P. falciparum* infection. In western Thailand, a region of low endemicity, the pyrogenic density was 180 parasites/μl, compared to 1000 parasites/μl observed in *P. falciparum* infection⁷. These estimates are similar to those observed in volunteers and malariotherapy patients²⁰. In keeping with this the host inflammatory response is activated to a greater extent during infections with *P. vivax*, with plasma levels of fever-inducing cytokines such as TNF-α being higher in vivax malaria compared to *P. falciparum* infections with similar parasitemia^{21, 22}.

In addition to lower peripheral parasitemias, patients with *P. vivax* infections also tend to present with all parasite stages visible on the peripheral blood film. In contrast the late stages of *P. falciparum* are usually absent or present in low numbers, reflecting cytoadherence in the postcapillary venules. The latter is fundamental to the etiology of severe and placental malaria in *P. falciparum* infections²³. In contrast *P. vivax*-infected red blood cells become increasingly more deformable as they mature²⁴ and are usually considered not to cytoadhere or sequester in the microvasculature. These characteristics underlie the reason why severe pathology in vivax infections is much less common than with *P. falciparum* infection. Interestingly recent studies have challenged this paradigm, by suggesting that *P. vivax*-infected red cells may sequester in organs such as the lung²⁵.

One of the most important differences between the plasmodial species infecting humans lies in the ability of *P. vivax* and *P. ovale* to relapse following the cure of the original infection. A proportion of sporozoites do not undergo immediate development in the invaded hepatocytes. Instead they remain dormant in the liver, as hypnozoites, for prolonged periods of time before developing and causing recurrent infection. *P. vivax* strains from different geographic areas display widely different relapse patterns, reflecting evolutionary adaptation to local environmental conditions that optimize transmission potential of the parasite. Strains from tropical areas are characterized by early primary infection followed by frequent (10-14) relapses 3-6 weeks apart²⁶. Whereas in temperate areas primary infection tends to occur later with intervals up to one year and fewer and later relapses to overcome prolonged periods of the year when transmission to the mosquito vector is unfavorable²⁷. The ability to relapse renders *P. vivax* resilient to eradication from both the human host and the environment.

Clinical manifestations

Clinical disease is associated with chills, vomiting, malaise, headache, fever and myalgia. These symptoms are non-specific and cannot be distinguished reliably from other febrile illnesses or other malarias⁷. High fever and rigors are more common in vivax than falciparum malaria, reflecting synchronicity of schizont rupture. The classic paroxysms of fever lasting 4-8 hours and occurring with 48-56 hour periodicity, take several asexual cycles to develop in primary infections, although relapses often start synchronously with rigors²⁸. *Plasmodium vivax* has a reputation as a benign infection, when compared to the severe manifestations frequently observed with untreated *P. falciparum*. However in the pre-antibiotic era vivax malaria resulted in a chronic debilitating febrile illness which could last for years and was associated with hypoproteinemia and edema and dramatic weight loss akin to kwashiorkor²⁶. Even today with access to effective antimalarials severe and fatal infections can occur with *P. vivax*. It has long been recognized that splenic rupture is a life-threatening, though rare, complication²⁹. More recently *P. vivax* has been shown to cause severe anemia, respiratory distress, malnutrition³⁰ and possibly coma^{31, 32, 33}.

In areas endemic for *P. vivax*, prevalence usually reaches a peak in young infants and children. In impoverished communities anemia from malnutrition, worm infestations and falciparum malaria can be near-universal in this age group. Recurrent hemolysis (of both parasitized and non-parasitized red cells) 34 and dyserythropoiesis from relapsing vivax malaria exacerbate this multifactorial anemia. Although most studies have not quantified the proportion attributable to vivax malaria, in some areas *P. vivax* infections are likely to be the most important determinant of anemia in infants. A case in point comes from southern Papua, Indonesia where almost 38% of patients hospitalized with malaria are anaemic (Hb<7g/dl). In this region 40% of severe anaemia (Hb<5g/dl) in infants can be attributed to infections with *P. vivax*, a rate almost three fold higher than that for *P. falciparum* 8. Similar findings in Venezuela also suggest that anaemia may be more severe and frequent in *P. vivax* infections than in *P. falciparum* 35. When compounded by even mild respiratory dysfunction and malnutrition such degrees of anaemia are likely to be an important contributor to morbidity, hospital stay and even mortality 30.

Pregnant women are particularly vulnerable to malaria. *Plasmodium falciparum* sequesters in the placenta resulting in pathological changes and compromises materno-fetal transport resulting in adverse outcomes in both mother and baby. The burden of *P. vivax* malaria in pregnancy is less well described. *P. vivax* does not appear to sequester in the placenta 36 and is associated with less pronounced histological changes in the placenta, the main process being increased haemozoin deposition 36. However *P. vivax* may still exert an adverse effect on the fetus through maternal anemia and the induction of a strong local inflammatory response, both of which interfere with utero-placental hemodynamics 37. Clinical findings from Thailand and India have shown that vivax malaria during pregnancy causes maternal anemia and a significant reduction in mean birth weight (circa 110g) which is about 60% of that observed with falciparum malaria 38, 39; this almost certainly contributes to infant mortality. Interestingly, in contrast with falciparum malaria, the birthweight reduction is greater in multigravidae than primigravidae.

There have now been at least 18 case reports of non-cardiogenic pulmonary edema/acute lung injury in vivax malaria, almost all of which have excluded concurrent infection with *P. falciparum* 25, 40, 41. All of the cases developed after commencement of antimalarial chemotherapy, raising the possibility of a pulmonary inflammatory response to parasite killing 42. The possible sequestration of *P. vivax* in the pulmonary microvasculature 25 may target this inflammatory response to the lung. Although further studies are needed, these findings and the observation that over 50% of patients with vivax malaria present with cough 25, 42 suggest that, as with *P. falciparum* 43, there may be an important overlap between the clinical features of acute respiratory infections and acute vivax malaria. There have also been several reports of coma associated with vivax malaria 31, 32, 33 though most have not excluded concurrent infection with *P. falciparum* or other pathogens with central nervous system manifestations.

These reports of severe manifestations following vivax malaria challenge the usual perception of *P. vivax* as a benign infection. The spectrum of disease caused by *P. vivax* in Papua New Guinea and Papua, Indonesia, appear particularly bad; indeed in southern Papua 16% of all cases of severe malaria admitted to hospital were attributable to *P. vivax* 8. Reports from India and Sri Lanka also highlight the broad range of pathology associated with *P. vivax* 2, 33. However these rates may not necessarily be extrapolated to other endemic areas. Differences in parasite virulence, host susceptibility, age of exposure as well as parasite factors such as antimalarial drug resistance may play a crucial role in modulating the clinical presentation. Alternatively the spectrum of disease in other areas may simply be under reported, particularly if severe pathology is mistakenly attributed to co-infection or misdiagnosis in speciation.

Mixed infections

In regions where *P. falciparum* and *P. vivax* coexist mixed-species infection are common and yet rarely reported. Surveys usually report rates less than 2% and yet careful clinical studies record rates up to 30% and this figure is even higher when PCR detection methods are used 44. Concurrent infections with different plasmodium species may have important implications on the host response and development of cross-species immunity 45. Indeed in Thailand where this has been particularly studied, mixed infections with *P. vivax* appear to attenuate the severity of disease with *P. falciparum* reducing the risk of severe malaria 46, decreasing the risk of treatment failure 47, lowering gametocyte carriage 48 and reducing the prevalence of anaemia 49. However in higher transmission areas and areas of emerging drug resistance, the additive burden of severe malarial anemia and maternal malaria has not been addressed in detail. The potential for *P. vivax* to attenuate falciparum malaria requires further characterization, and has significant implications for vivax-only vaccination strategies, and the deployment of drugs such as chloroquine which have lost efficacy against *P. falciparum* but still retain it against *P. vivax*.

Socioeconomic Burden

The appreciation of the socio-economic burden of malaria has risen over the last decade and been a major factor in raising its global profile and the funds dedicated to combating the disease. Falciparum malaria alone is estimated to have reduced the Gross Domestic Product of 31 African countries by almost 10% 50. Although neglected, a number of observations suggest that *P. vivax* is also likely to exert a considerable economic toll. The incidence of *P. vivax* varies between regions, and age groups, however since *P. vivax* relapses in 20-80% of patients 27. This ensures that even in low transmission areas, up to 20% of the population can have a symptomatic infection each year with a cumulative experience of 10-30 episodes of malaria during a lifetime 2.

The socio-economic burden of *P. vivax* infection is not known. Based on the estimated number of clinical episodes per year (106 - 313 million), assuming full treatment coverage with drug costs of \$0.1 per course of chloroquine and non-drug treatment costs of \$8.3 51, the direct cost of treatment is between US\$0.9 - 2.7 billion per year. Since each symptomatic infection is associated with at least 3 days absence from school or work (unpublished data), the overall global cost of *P. vivax* infection to the individual in terms of lost productivity (assuming a daily wage of US\$1.5 per day), healthcare costs and transport to clinics can be conservatively estimated as being between US\$ 1.4 - 4.0 billion per year.

These immediate costs are likely to be augmented by recurrent *P. vivax* infections in children. Longitudinal studies from Sri Lanka suggest that repeated attacks of malaria have an adverse impact on the school performance of children 52, 53. Intuitively, recurrent vivax malaria will also result in anemia, malnutrition, growth retardation, stunting of development, and impaired economic productivity later in life, though detailed studies are lacking.

The burden of vivax malaria is felt not only at the individual level but also by health care providers. In many parts of Asia and South America, where *P. vivax* accounts for more than half of the cases of malaria, institutional healthcare costs are appreciably higher due to high rates of clinic attendance and hospitalization. In Thailand and Indonesia almost 30% of patients hospitalized with malaria are associated with pure *P. vivax* infections 8, 12. Again further studies are needed to quantify these costs more precisely.

Diagnosis and Management of Vivax Malaria

While microscopy remains the mainstay of diagnosis of vivax malaria, lack of access to good quality microscopy services in many endemic regions limits the reliability of diagnosis

(as well as contributing to the underestimation of cases). HRP-2-based rapid diagnostic tests (RDTs) are usually sensitive for the diagnosis of *P. falciparum*, although aldolase-based and parasite lactic dehydrogenase-based RDTs have suboptimal sensitivity for *P. vivax* 54, 55, limiting the utility of RDTs for vivax diagnosis 56.

Chloroquine has been the mainstay of treatment for acute vivax malaria for more than 50 years with dosing recommendations generally similar to those for *P. falciparum* (25mg base/kg up to 1.55g, given in three or four doses over 3 days). After eradication of the asexual stages of *P. vivax* from the peripheral blood, patients are at risk of relapse from the dormant liver stage. In equatorial regions such relapses occur in 20-80% of patients 27, 57. Chloroquine has potent activity against asexual stages, but no activity against hypnozoites. However its long terminal elimination ensures that plasma concentrations of chloroquine are sustained above the minimum inhibition concentration for at least 28 days and thus are capable of suppressing the first relapse which in tropical zones occurs at about 21 days 58. The prevention of further relapses necessitates eradication of the dormant liver stages; however, only one antimalarial agent is registered with such activity, the 8-aminoquinoline primaquine. The standard recommendation for radical cure of *P. vivax* has been 15mg primaquine daily over 14 days 27. In some areas, particularly the Indian subcontinent, five day courses are recommended despite there being no evidence that they prevent relapse. The efficacy of the 14 day regimen varies considerably with relative resistance documented in Oceania and parts of Asia 59, 60. Several unsubstantiated reports also suggest that primaquine efficacy may be waning elsewhere 27. The problem is particularly bad in Papua and Papua New Guinea where *P. vivax* demonstrates marked tolerance to primaquine 61, 62. Higher doses or longer courses have been advocated and may be more effective 63; however, in practice, long courses of unsupervised therapy are rarely adhered to and thus likely to be ineffective. Furthermore, primaquine is contraindicated in infancy and pregnancy and causes hemolysis in G6PD deficient individuals. In endemic settings shorter alternatives are needed urgently. Short course tafenoquine has potential 64, but is not registered and concerns about its prolonged hemolytic potential has tempered enthusiasm for its use in endemic areas where routine screening for G6PD deficiency is not possible.

Chloroquine resistance (CQR)—Whereas chloroquine-resistant *P. falciparum* was first documented over 50 years ago, drug resistant strains of *P. vivax* have taken much longer to emerge. This may reflect species differences in the underlying molecular mechanisms of resistance or lower selection pressure because of differences in the biology of gametocytogenesis. Gametocytogenesis in *P. falciparum* occurs after the appearance of symptoms and is refractory to schizontocidal drugs, thus favoring the transmission of resistant genotypes. In contrast gametocytes occur earlier in *P. vivax* compared to *P. falciparum* infections and are eliminated rapidly by schizontocidal agents, ensuring early transmission prior to selection.

The first case of CQR *P. vivax* (CQRPV) was reported in 1989 from Papua New Guinea 65 and was soon followed by reports from northern Papua, Indonesia 66, 67, 68. By 1995, in some parts of Papua almost all patients with vivax malaria treated with chloroquine monotherapy failed therapy within 28 days 69. Other studies subsequently confirmed a high prevalence of chloroquine-resistance elsewhere in Papua 70 and other parts of Indonesia 71, 72. Sporadic cases have also been reported from Burma 73, South America 74, 75, Viet Nam 76, and Turkey 77; see figure 1. In contrast chloroquine mostly retains its efficacy against *P. vivax* in Thailand and India, 57, 78, 79 Despite these reports, the global prevalence of CQRPV is still poorly defined. In a recent systematic review only 11% (47/435) of published antimalarial drug trials between 1966 and 2002 addressed the efficacy of antimalarial drugs against *P. vivax* 80. This reflects both the inherent difficulties associated with the *in vivo* test for relapsing malarias and, in the absence of any empirical

evidence, the belief that established protocols continue to be effective. The latter was a major reason why policies were so slow to respond to the collapse of chloroquine efficacy against *P. falciparum* in sub-Saharan Africa a decade ago. The WHO 1999 Guidelines recommended a 14 day follow up for the *in vivo* diagnosis of CQR *P. vivax* and such a short duration is incapable of detecting early decline in antimalarial therapeutic efficacy 81. The 2005 WHO guidelines have extended follow up to 28 days, which improves the sensitivity of the test, but at the expense of increasing confounding results from reinfection and relapse. Parasite genotyping has been useful in discriminating reinfection and recrudescence in *P. falciparum*, but the use of a similar strategy in *P. vivax* is more complex 82. Relapses can occur either from the primary infection (in which case they are identical to recrudescence infections) or from a previous infection (in which case they may be misclassified as reinfections): allocating a treatment outcome to a recurrent parasitaemia is therefore not possible. In practice recurrent infections occurring within 28 days of supervised chloroquine administration will be growing in the presence of chloroquine concentrations normally considered above those required to inhibit parasite multiplication and thus can be considered resistant 83. Monitoring the uncorrected cure rate at day 28 is therefore a reasonable indicator of declining chloroquine efficacy which can be confirmed by analysis of whole blood chloroquine concentrations to ensure adequate drug absorption.

In vitro susceptibility assays provide another means of assessing drug susceptibility of *Plasmodium* spp. free from the confounders of host immunity, relapse and reinfection. Although these tests have been used in *P. falciparum* for more than 30 years, their application in *P. vivax* has been more difficult to develop because of the inability to culture the parasite through schizogony in an ex-vivo assay. Recently several groups from Thailand where *P. vivax* responds well to chloroquine have reported successful adaptation of schizont maturation assays deriving IC50 values for *P. vivax* to chloroquine in the range of 30-120nM 79, 84, 85. Preliminary studies from Papua, Indonesia, where clinical studies have established the presence of high grade CQR, demonstrate that chloroquine susceptibility of *P. vivax* is five fold lower than that reported in Thailand 86. These findings suggest that *in vitro* testing may prove useful in monitoring for the emergence of resistance.

The other important tool for monitoring antimalarial drug resistance is tracking the prevalence of genetic markers of resistance. However our current understanding of the molecular mechanisms of CQR in *P. vivax* is limited and preliminary studies suggest that resistance mechanisms may be different from that seen in *P. falciparum* 87. Renewed interest in identifying putative molecular markers of CQRPV has been stimulated by the recent completion of the vivax genome project.

Treatment of resistant *P. vivax*

In vivo drug studies on strains of *P. vivax* sensitive to chloroquine have demonstrated the efficacy of artemisinin derivatives, mefloquine, quinine and halofantrine 88, however few studies have addressed suitable treatment regimens for CQR vivax malaria 83. *P. vivax* has previously been regarded as intrinsically resistant to antifolates. It is not; but resistance develops readily 68, 89, through the sequential acquisition of mutations in *Pvdhfr* 68, 90, 91. The prevalence of antifolate resistance is similar to that of *P. falciparum* with high levels of resistance in much of SE Asia 92 (Laos is a notable exception) and lesser degrees of resistance in the Indian subcontinent.

In Indonesia the efficacy of amodiaquine is superior to that of chloroquine, but in regions where high levels of CQR predominate, day 28 failure rates exceed 25% suggesting amodiaquine monotherapy is not a suitable alternative once high grade resistance has been reached 93. Better success in the same region has been obtained with mefloquine and halofantrine which retain almost 100% cure rates by day 28 94, 95. Atovaquone-proguanil

plus primaquine also showed excellent efficacy against CQR *P. vivax* 96, however the high cost of this regimen (~\$40) virtually precludes its use in endemic communities.

The artemisinin derivatives are highly potent antimalarials and are even more active against *P. vivax* than *P. falciparum* 97. Artemisinin combination therapy (ACT) is now widely advocated for the treatment of *P. falciparum* infections. In practice only a minority of infections have correct species identification prior to treatment and therefore in Asia and South America it is highly likely that other species will also be treated with ACT. Despite this, only three studies have addressed the efficacy of these combinations against *P. vivax*. In the first, a three day course of artesunate plus sulfadoxine-pyrimethamine resulted in a recurrence rate of 10.5% by day 28 68. In two subsequent studies of patients with pure *P. vivax* infections, recurrence rates by day 28 were significantly higher after artemether-lumefantrine (23%) and amodiaquine-artesunate (12%) than after dihydroartemisinin piperazine (3.6%) 93, 98. None of these antimalarial drugs have any efficacy on the hypnozoite stages of *P. vivax* and hence the difference in cure rates is likely to be a consequence of the difference between the terminal elimination half life of lumefantrine (~4 days), amodiaquine (18 days) and that of piperazine (28-35 days). Piperazine, like chloroquine, suppresses the first relapse whereas lumefantrine and amodiaquine do not. In areas where primaquine can not be supervised such post treatment prophylaxis afforded by drugs with long half lives will not prevent subsequent relapses, but will provide the only practical means currently available of delaying the timing of clinical illness from these relapses. The latter affords patients a longer period free from symptomatic malaria, decreases the risk of anaemia and reduces significantly gametocyte carriage and thus the transmission potential to the mosquito vector 93. Although longitudinal studies are needed to confirm these findings, when choosing an alternative to chloroquine in communities where CQR *vivax* malaria is endemic the relevance of post treatment prophylaxis should not be overlooked.

Control of vivax malaria

Malaria control programs generally focus on providing good vector control, early diagnosis and access to effective antimalarial regimens, preferably with anti-gametocyte activity to reduce transmission. In areas where both species are present, ACT-treatment based programs have greater impact on *P. falciparum* than *P. vivax* 12, 99. Intensive eradication programs were successful in Europe, US, Australia, and in the 1940s-1960s both *P. falciparum* and *P. vivax* were almost eradicated from India with intensive DDT-based vector control and effective chloroquine chemotherapy 100. The subsequent abandonment of DDT-based vector control led to a resurgence of both species in South Asia. Control measures remain limited in most areas of Asia, South America and temperate regions of the middle and Far East and are compounded by political instability in central Asia where there has been a resurgence of *vivax* malaria. This lack of progress is of particular concern in view of the availability of both DDT and chloroquine, the latter remaining inexpensive and effective against *vivax* malaria in most areas. Chloroquine-resistant strains of the parasite are already firmly established in Papua New Guinea and eastern Indonesia and as they spread further afield will impact significantly on current control programme.

The drive to tackle *P. vivax* is very much dependent upon the perception of the threat that it poses. The latter has been hampered by an under-appreciation of the morbidity and mortality from *vivax* malaria, and the paucity of literature focused on this species. A crucial step in recruiting the interest of ministries of health, policy makers, researchers and funding bodies will be the detailed characterization of the clinical epidemiology and economic burden of *P. vivax* in different geographical areas. From here our knowledge and experience with *P. falciparum*, provides a useful framework with which to tackle perhaps the greater challenges that we face in controlling *P. vivax*.

Acknowledgments

We thank Simon Hay, Kathryn Maitland, Bob Snow, and Shunmay Yeung for their helpful comments on the manuscript. RP is funded by a Wellcome Trust Career Development Award (074637). CAG is supported by a Wellcome Trust Project grant (#076951) attached to the Malaria Atlas Project (MAP, <http://www.map.ox.ac.uk>). NJW is a Wellcome Trust Principal Fellow. NA is supported by an NHMRC Practitioner Fellowship.

References

1. Breman JG, Alilio MS, Mills A. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. *Am J Trop Med Hyg.* 2004; 71:1–15. [PubMed: 15331814]
2. Mendis K, Sina BJ, Marchesini P, Carter R. The neglected burden of *Plasmodium vivax* malaria. *Am J Trop Med Hyg.* 2001; 64:97–106. [PubMed: 11425182]
3. Guerra CA, Snow RW, Hay SI. Mapping the global extent of malaria in 2005. *Trends Parasitol.* 2006
4. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. The global distribution and population at risk of malaria: past, present, and future. *Lancet Infect Dis.* 2004; 4:327–36. [PubMed: 15172341]
5. Snow RW, Hay SI. Comparing methods of estimating the global morbidity burden from *Plasmodium falciparum* malaria. *Am J Trop Med Hyg.* 2006; 74:189–90. [PubMed: 16474068]
6. Carter R, Mendis K. Measuring malaria. *Am J Trop Med Hyg.* 2006; 74:187–8. [PubMed: 16474067]
7. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maelankirri L, Chongsuphajaisiddhi T, Nosten F. The epidemiology of malaria in a Karen population on the western border of Thailand. *Trans R Soc Trop Med Hyg.* 1996; 90:105–11. [PubMed: 8761562]
8. Tjitra, E.; Warikar, N.; Ebsworth, EP.; Kenangalem, E.; Sugiarto, P.; Okoseray, MJ.; Rini, J.; Anstey, NM.; Price, RN. Major burden of *P.vivax* infection in Papua, Indonesia; A region with high levels of chloroquine resistance; 16th IFTM Medicine in the Tropics; Marseille, France. 2005;
9. Zhou G, Sirichaisinthop J, Sattabongkot J, Jones J, Bjornstad ON, Yan G, Cui L. Spatio-temporal distribution of *Plasmodium falciparum* and *P. Vivax* malaria in Thailand. *Am J Trop Med Hyg.* 2005; 72:256–62. [PubMed: 15772317]
10. Duarte EC, Gyorkos TW, Pang L, Abrahamowicz M. Epidemiology of malaria in a hypoendemic Brazilian Amazon migrant population: a cohort study. *Am J Trop Med Hyg.* 2004; 70:229–37. [PubMed: 15031509]
11. Singh N, Nagpal AC, Saxena A, Singh MP. Changing scenario of malaria in central India, the replacement of *Plasmodium vivax* by *Plasmodium falciparum* (1986–2000). *Trop Med Int Health.* 2004; 9:364–71. [PubMed: 14996366]
12. Carrara VI, Sirilak S, Thonglairuam J, Rojanawatsirivet C, Proux S, Gilbos V, Brockman A, Ashley EA, McGready R, Krudsood S, Leemingsawat S, Looareesuwan S, Singhasivanon P, White N, Nosten F. Deployment of Early Diagnosis and Mefloquine-Artesunate Treatment of *Falciparum* Malaria in Thailand: The Tak Malaria Initiative. *PLoS Med.* 2006; 3:e183. [PubMed: 16719547]
13. Cattani JA, Tulloch JL, Vrbova H, Jolley D, Gibson FD, Moir JS, Heywood PF, Alpers MP, Stevenson A, Clancy R. The epidemiology of malaria in a population surrounding Madang, Papua New Guinea. *Am J Trop Med Hyg.* 1986; 35:3–15. [PubMed: 3511748]
14. Roshanravan B, Kari E, Gilman RH, Cabrera L, Lee E, Metcalfe J, Calderon M, Lescano AG, Montenegro SH, Calampa C, Vinetz JM. Endemic malaria in the Peruvian Amazon region of Iquitos. *Am J Trop Med Hyg.* 2003; 69:45–52. [PubMed: 12932096]
15. Field, JW.; Shute, PG. The microscopic diagnosis of human malaria. Institute for medical research; Kuala Lumpur: 1956.
16. Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype, FyFy. *N Engl J Med.* 1976; 295:302–4. [PubMed: 778616]
17. Ryan JR, Stoute JA, Amon J, Dunton RF, Mtalib R, Koros J, Owour B, Luckhart S, Wirtz RA, Barnwell JW, Rosenberg R. Evidence for transmission of *Plasmodium vivax* among a duffy

- antigen negative population in Western Kenya. *Am J Trop Med Hyg.* 2006; 75:575–81. [PubMed: 17038676]
18. Simpson JA, Silamut K, Chotivanich K, Pukrittayakamee S, White NJ. Red cell selectivity in malaria: a study of multiple-infected erythrocytes. *Trans R Soc Trop Med Hyg.* 1999; 93:165–8. [PubMed: 10450440]
 19. Ross, Thomson. Some enumerative studies on malarial fever. *Proceedings of the Royal Society.* 1911; 83:159–173.
 20. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of the effect of fever and microgametocyte count on mosquito infection on humans infected with *Plasmodium vivax*. *Am J Trop Med Hyg.* 2004; 70:638–41. [PubMed: 15211005]
 21. Karunaweera ND, Grau GE, Gamage P, Carter R, Mendis KN. Dynamics of fever and serum levels of tumor necrosis factor are closely associated during clinical paroxysms in *Plasmodium vivax* malaria. *Proc Natl Acad Sci U S A.* 1992; 89:3200–3. [PubMed: 1565611]
 22. Hemmer CJ, Holst FG, Kern P, Chiwakata CB, Dietrich M, Reisinger EC. Stronger host response per parasitized erythrocyte in *Plasmodium vivax* or ovale than in *Plasmodium falciparum* malaria. *Trop Med Int Health.* 2006; 11:817–23. [PubMed: 16772003]
 23. Rogerson SJ, Grau GE, Hunt NH. The microcirculation in severe malaria. *Microcirculation.* 2004; 11:559–76. [PubMed: 15513866]
 24. Suwanarusk R, Cooke BM, Dondorp AM, Silamut K, Sattabongkot J, White NJ, Udomsangpetch R. The deformability of red blood cells parasitized by *Plasmodium falciparum* and *P. vivax*. *J Infect Dis.* 2004; 189:190–4. [PubMed: 14722882]
 25. Anstey NM, Handojo T, Pain MC, Kenangalem E, Tjitra E, Price RN, Maguire GP. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and posttreatment alveolar-capillary inflammation. *J Infect Dis.* 2007; 195:589–96. [PubMed: 17230420]
 26. Kitchen, SF. *Malariology.* W. B. Saunders & Co.; London: 1939.
 27. Baird JK, Hoffman SL. Primaquine therapy for malaria. *Clin Infect Dis.* 2004; 39:1336–45. [PubMed: 15494911]
 28. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of reinfection of humans with *Plasmodium vivax*. *Am J Trop Med Hyg.* 2004; 70:642–4. [PubMed: 15211006]
 29. Covell G. Spontaneous rupture of the spleen. *Trop Dis Bull.* 1955; 52:705–23. [PubMed: 13256640]
 30. Williams TN, Maitland K, Phelps L, Bennett S, Peto TE, Viji J, Timothy R, Clegg JB, Weatherall DJ, Bowden DK. *Plasmodium vivax*: a cause of malnutrition in young children. *Qjm.* 1997; 90:751–7. [PubMed: 9536339]
 31. Beg MA, Khan R, Baig SM, Gulzar Z, Hussain R, Smego RA Jr. Cerebral involvement in benign tertian malaria. *Am J Trop Med Hyg.* 2002; 67:230–2. [PubMed: 12408660]
 32. Genton, B.; D'Acremont, V.; Lorry, K.; Baea, K.; Reeder, JC.; Mueller, I. *Plasmodium Vivax* is associated with severe malaria in Papua New Guinean children; 54th Annual meeting - American Society of tropical Medicine and Hygiene; Washington. 2005;
 33. Kochar DK, Saxena V, Singh N, Kochar SK, Kumar SV, Das A. *Plasmodium vivax* malaria. *Emerg Infect Dis.* 2005; 11:132–4. [PubMed: 15705338]
 34. Collins WE, Jeffery GM, Roberts JM. A retrospective examination of anemia during infection of humans with *Plasmodium vivax*. *Am J Trop Med Hyg.* 2003; 68:410–2. [PubMed: 12875288]
 35. Rodriguez-Morales AJ, Sanchez E, Vargas M, Piccolo C, Colina R, Arria M, Franco-Paredes C. Is anemia in *Plasmodium vivax* malaria more frequent and severe than in *Plasmodium falciparum*? *Am J Med.* 2006; 119:e9–10. [PubMed: 17071151]
 36. McGready R, Davison BB, Stepniewska K, Cho T, Shee H, Brockman A, Udomsangpetch R, Looareesuwan S, White NJ, Meshnick SR, Nosten F. The effects of *Plasmodium falciparum* and *P. vivax* infections on placental histopathology in an area of low malaria transmission. *Am J Trop Med Hyg.* 2004; 70:398–407. [PubMed: 15100454]
 37. Brabin BJ, Romagosa C, Abdelgalil S, Menendez C, Verhoeff FH, McGready R, Fletcher KA, Owens S, D'Alessandro U, Nosten F, Fischer PR, Ordi J. The sick placenta-the role of malaria. *Placenta.* 2004; 25:359–78. [PubMed: 15081631]

38. Nosten F, McGready R, Simpson JA, Thwai KL, Balkan S, Cho T, Hkijaroen L, Looareesuwan S, White NJ. Effects of *Plasmodium vivax* malaria in pregnancy. *Lancet*. 1999; 354:546–9. [PubMed: 10470698]
39. Singh N, Shukla MM, Sharma VP. Epidemiology of malaria in pregnancy in central India. *Bull World Health Organ*. 1999; 77:567–72. [PubMed: 10444880]
40. Torres JR, Perez H, Postigo MM, Silva JR. Acute non-cardiogenic lung injury in benign tertian malaria. *Lancet*. 1997; 350:31–2. [PubMed: 9217722]
41. Pukrittayakamee S, Chantira A, Vanijanonta S, White NJ. Pulmonary oedema in vivax malaria. *Trans R Soc Trop Med Hyg*. 1998; 92:421–2. [PubMed: 9850397]
42. Anstey NM, Jacups SP, Cain T, Pearson T, Ziesing PJ, Fisher DA, Currie BJ, Marks PJ, Maguire GP. Pulmonary manifestations of uncomplicated falciparum and vivax malaria: cough, small airways obstruction, impaired gas transfer, and increased pulmonary phagocytic activity. *J Infect Dis*. 2002; 185:1326–34. [PubMed: 12001051]
43. O'Dempsey TJ, McArdle TF, Laurence BE, Lamont AC, Todd JE, Greenwood BM. Overlap in the clinical features of pneumonia and malaria in African children. *Trans R Soc Trop Med Hyg*. 1993; 87:662–5. [PubMed: 8296367]
44. Mayxay M, Pukrittayakamee S, Newton PN, White NJ. Mixed-species malaria infections in humans. *Trends Parasitol*. 2004; 20:233–40. [PubMed: 15105024]
45. Maitland K, Williams TN, Newbold CI. *Plasmodium vivax* and *P. falciparum*: Biological interactions and the possibility of cross-species immunity. *Parasitol Today*. 1997; 13:227–31. [PubMed: 15275075]
46. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. *Trans R Soc Trop Med Hyg*. 1997; 91:256–62. [PubMed: 9231189]
47. Price RN, Nosten F, Luxemburger C, van Vugt M, Phaipun L, Chongsuphajaisiddhi T, White NJ. Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. *Trans R Soc Trop Med Hyg*. 1997; 91:574–7. [PubMed: 9463672]
48. Price R, Nosten F, Simpson JA, Luxemburger C, Phaipun L, ter Kuile F, van Vugt M, Chongsuphajaisiddhi T, White NJ. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. *Am J Trop Med Hyg*. 1999; 60:1019–23. [PubMed: 10403336]
49. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkijaroen L, ter Kuile F, Chongsuphajaisiddhi T, White NJ. Factors contributing to anemia after uncomplicated falciparum malaria. *Am J Trop Med Hyg*. 2001; 65:614–22. [PubMed: 11716124]
50. Gallup JL, Sachs JD. The economic burden of malaria. *Am J Trop Med Hyg*. 2001; 64:85–96. [PubMed: 11425181]
51. WHO-CHOICE_Study, Mean cost of health centre consultation cost for WPR B and SEAR B regions. http://www.who.int/choice/costs/unit_costs/en/index.html.
52. Fernando SD, Gunawardena DM, Bandara MR, De Silva D, Carter R, Mendis KN, Wickremasinghe AR. The impact of repeated malaria attacks on the school performance of children. *Am J Trop Med Hyg*. 2003; 69:582–8. [PubMed: 14740872]
53. Fernando D, de Silva D, Wickremasinghe R. Short-term impact of an acute attack of malaria on the cognitive performance of schoolchildren living in a malaria-endemic area of Sri Lanka. *Trans R Soc Trop Med Hyg*. 2003; 97:633–9. [PubMed: 16117954]
54. Pattanasin S, Proux S, Chompasuk D, Luwiradaj K, Jacquier P, Looareesuwan S, Nosten F. Evaluation of a new *Plasmodium* lactate dehydrogenase assay (OptiMAL-IT) for the detection of malaria. *Trans R Soc Trop Med Hyg*. 2003; 97:672–4. [PubMed: 16117960]
55. Tjitra E, Suprianto S, Dyer M, Currie BJ, Anstey NM. Field evaluation of the ICT malaria P.f/P.v immunochromatographic test for detection of *Plasmodium falciparum* and *Plasmodium vivax* in patients with a presumptive clinical diagnosis of malaria in eastern Indonesia. *J Clin Microbiol*. 1999; 37:2412–7. [PubMed: 10405377]
56. Bell D, Peeling RW. Evaluation of rapid diagnostic tests: malaria. *Nat Rev Microbiol*. 2006; 4:S34–8. [PubMed: 17034070]

57. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F. Treatment of vivax malaria on the western border of Thailand. *Trans R Soc Trop Med Hyg.* 1999; 93:433–8. [PubMed: 10674098]
58. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL. Diagnosis of resistance to chloroquine by *Plasmodium vivax*: timing of recurrence and whole blood chloroquine levels. *Am J Trop Med Hyg.* 1997; 56:621–6. [PubMed: 9230792]
59. Bunnag D, Karbwang J, Thanavibul A, Chittamas S, Ratanapongse Y, Chalermrut K, Bangchang KN, Harinasuta T. High dose of primaquine in primaquine resistant vivax malaria. *Trans R Soc Trop Med Hyg.* 1994; 88:218–9. [PubMed: 8036680]
60. Doherty JF, Day JH, Warhurst DC, Chiodini PL. Treatment of *Plasmodium vivax* malaria--time for a change? *Trans R Soc Trop Med Hyg.* 1997; 91:76. [PubMed: 9093635]
61. Ehrman FC, Ellis JM, Young MD. *Plasmodium vivax* Chesson strain. *Science.* 1945; 101:377. [PubMed: 17780321]
62. Clyde DF, McCarthy VC. Radical cure of Chesson strain vivax malaria in man by 7, not 14, days of treatment with primaquine. *Am J Trop Med Hyg.* 1977; 26:562–3. [PubMed: 326072]
63. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? *Trends Parasitol.* 2003; 19:115–20. [PubMed: 12643993]
64. Nasveld P, Kitchener S. Treatment of acute vivax malaria with tafenoquine. *Trans R Soc Trop Med Hyg.* 2005; 99:2–5. [PubMed: 15550254]
65. Rieckmann KH, Davis DR, Hutton DC. *Plasmodium vivax* resistance to chloroquine? *Lancet.* 1989; 2:1183–4. [PubMed: 2572903]
66. Baird JK, Basri H, Purnomo, Bangs MJ, Subianto B, Patchen LC, Hoffman SL. Resistance to chloroquine by *Plasmodium vivax* in Irian Jaya, Indonesia. *Am J Trop Med Hyg.* 1991; 44:547–52. [PubMed: 1676566]
67. Murphy GS, Basri H, Purnomo, Andersen EM, Bangs MJ, Mount DL, Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, et al. Vivax malaria resistant to treatment and prophylaxis with chloroquine. *Lancet.* 1993; 341:96–100. [PubMed: 8093414]
68. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to *Plasmodium vivax* dhfr mutations. *Antimicrob Agents Chemother.* 2002; 46:3947–53. [PubMed: 12435700]
69. Sumawinata IW, Bernadeta, Leksana B, Sutanihardja A, Purnomo, Subianto B, Sekartuti, Fryauff DJ, Baird JK. Very high risk of therapeutic failure with chloroquine for uncomplicated *Plasmodium falciparum* and *P. vivax* malaria in Indonesian Papua. *Am J Trop Med Hyg.* 2003; 68:416–20. [PubMed: 12875290]
70. Ratcliff A, Siswanto H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Therapeutic response of multidrug-resistant *Plasmodium falciparum* and *P. vivax* to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. *Trans R Soc Trop Med Hyg.* 2007; 101:351–359. [PubMed: 17028048]
71. Baird JK, Sustriayu Nalim MF, Basri H, Masbar S, Leksana B, Tjitra E, Dewi RM, Khairani M, Wignall FS. Survey of resistance to chloroquine by *Plasmodium vivax* in Indonesia. *Trans R Soc Trop Med Hyg.* 1996; 90:409–11. [PubMed: 8882190]
72. Fryauff DJ, Tuti S, Mardi A, Masbar S, Patipelohi R, Leksana B, Kain KC, Bangs MJ, Richie TL, Baird JK. Chloroquine-resistant *Plasmodium vivax* in transmigrant settlements of West Kalimantan, Indonesia. *Am J Trop Med Hyg.* 1998; 59:513–8. [PubMed: 9790420]
73. Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O. Development of resistance to chloroquine by *Plasmodium vivax* in Myanmar. *Trans R Soc Trop Med Hyg.* 1995; 89:307–8. [PubMed: 7660445]
74. Soto J, Toledo J, Gutierrez P, Luzz M, Llinas N, Cedeno N, Dunne M, Berman J. *Plasmodium vivax* clinically resistant to chloroquine in Colombia. *Am J Trop Med Hyg.* 2001; 65:90–3. [PubMed: 11508397]
75. Phillips EJ, Keystone JS, Kain KC. Failure of combined chloroquine and high-dose primaquine therapy for *Plasmodium vivax* malaria acquired in Guyana, South America. *Clin Infect Dis.* 1996; 23:1171–3. [PubMed: 8922821]

76. Phan GT, de Vries PJ, Tran BQ, Le HQ, Nguyen NV, Nguyen TV, Heisterkamp SH, Kager PA. Artemisinin or chloroquine for blood stage *Plasmodium vivax* malaria in Vietnam. *Trop Med Int Health*. 2002; 7:858–64. [PubMed: 12358621]
77. Kurcer MA, Simsek Z, Zeyrek FY, Atay S, Celik H, Kat I, Topluoglu S. Efficacy of chloroquine in the treatment of *Plasmodium vivax* malaria in Turkey. *Ann Trop Med Parasitol*. 2004; 98:447–51. [PubMed: 15257793]
78. Valecha N, Joshi H, Eapen A, Ravinderan J, Kumar A, Prajapati SK, Ringwald P. Therapeutic efficacy of chloroquine in *Plasmodium vivax* from areas with different epidemiological patterns in India and their *Pvdhfr* gene mutation pattern. *Trans R Soc Trop Med Hyg*. 2006
79. Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K. Clinical-parasitological response and in-vitro sensitivity of *Plasmodium vivax* to chloroquine and quinine on the western border of Thailand. *Trans R Soc Trop Med Hyg*. 2006; 100:410–8. [PubMed: 16497347]
80. Myint HY, Tipmanee P, Nosten F, Day NP, Pukrittayakamee S, Looareesuwan S, White NJ. A systematic overview of published antimalarial drug trials. *Trans R Soc Trop Med Hyg*. 2004; 98:73–81. [PubMed: 14964805]
81. Stepniewska K, Taylor WR, Mayxay M, Price R, Smithuis F, Guthmann JP, Barnes K, Myint HY, Adjuik M, Olliaro P, Pukrittayakamee S, Looareesuwan S, Hien TT, Farrar J, Nosten F, Day NP, White NJ. In vivo assessment of drug efficacy against *Plasmodium falciparum* malaria: duration of follow-up. *Antimicrob Agents Chemother*. 2004; 48:4271–80. [PubMed: 15504852]
82. Cui L, Escalante AA, Imwong M, Snounou G. The genetic diversity of *Plasmodium vivax* populations. *Trends Parasitol*. 2003; 19:220–6. [PubMed: 12763428]
83. Baird JK. Chloroquine resistance in *Plasmodium vivax*. *Antimicrob Agents Chemother*. 2004; 48:4075–83. [PubMed: 15504824]
84. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman RE, Sattabongkot J. Simple in vitro assay for determining the sensitivity of *Plasmodium vivax* isolates from fresh human blood to antimalarials in areas where *P. vivax* is endemic. *Antimicrob Agents Chemother*. 2003; 47:170–3. [PubMed: 12499187]
85. Chotivanich K, Udomsangpetch R, Chierakul W, Newton PN, Ruangveerayuth R, Pukrittayakamee S, Looareesuwan S, White NJ. In vitro efficacy of antimalarial drugs against *Plasmodium vivax* on the western border of Thailand. *Am J Trop Med Hyg*. 2004; 70:395–7. [PubMed: 15100453]
86. Russell, BM.; R, S.; Chavchich, M.; Chalfein, F.; Kenangalem, E.; Cheng, Q.; Lek-Uthai, U.; Kosaisavee, V.; Brockman, A.; Nosten, F.; Jones, JW.; Anstey, NM.; Tjitra, E.; Price, RN. *Vivax Malaria Research: 2005 and Beyond*. Rockville: 2005. In vitro and molecular genotyping studies of chloroquine resistant and sensitive *Plasmodium vivax*.
87. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, Fidock DA, Su X, Collins WE, McCutchan TF, Wootton JC, Wellems TE. Evidence for different mechanisms of chloroquine resistance in 2 *Plasmodium* species that cause human malaria. *J Infect Dis*. 2001; 183:1653–61. [PubMed: 11343215]
88. Pukrittayakamee S, Chantira A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to different antimalarial drugs in vivax malaria. *Antimicrob Agents Chemother*. 2000; 44:1680–5. [PubMed: 10817728]
89. Darlow B, Vrbova H, Gibney S, Jolley D, Stace J, Alpers M. Sulfadoxine-pyrimethamine for the treatment of acute malaria in children of Papua New Guinea. II. *Plasmodium vivax*. *Am J Trop Med Hyg*. 1982; 31:10–3. [PubMed: 7036765]
90. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlier JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G. Novel point mutations in the dihydrofolate reductase gene of *Plasmodium vivax*: evidence for sequential selection by drug pressure. *Antimicrob Agents Chemother*. 2003; 47:1514–21. [PubMed: 12709316]
91. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK. Dihydrofolate reductase mutations in *Plasmodium vivax* from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. *J Infect Dis*. 2004; 189:744–50. [PubMed: 14767830]

92. Burns M, Baker J, Auliff AM, Gatton ML, Edstein MD, Cheng Q. Efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated *Plasmodium falciparum* malaria in East Timor. *Am J Trop Med Hyg.* 2006; 74:361–6. [PubMed: 16525092]
93. Ratcliff A, Siswanto H, Kenangalem E, Maritsela R, Wuwung RM, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN. Comparison of two fixed dosed artemisinin combinations for multi-drug resistant *falciparum* and *vivax* malaria in Papua, Indonesia. *Lancet.* 2007 In Press.
94. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL. Treatment of chloroquine-resistant *Plasmodium vivax* with chloroquine and primaquine or halofantrine. *J Infect Dis.* 1995; 171:1678–82. [PubMed: 7769318]
95. Maguire JD, Krisin, Marwoto H, Richie TL, Fryauff DJ, Baird JK. Mefloquine is highly efficacious against chloroquine-resistant *Plasmodium vivax* malaria and *Plasmodium falciparum* malaria in Papua, Indonesia. *Clin Infect Dis.* 2006; 42:1067–72. [PubMed: 16575721]
96. Lacy MD, Maguire JD, Barcus MJ, Ling J, Bangs MJ, Gramzinski R, Basri H, Sismadi P, Miller GB, Chulay JD, Fryauff DJ, Hoffman SL, Baird JK. Atovaquone/proguanil therapy for *Plasmodium falciparum* and *Plasmodium vivax* malaria in Indonesians who lack clinical immunity. *Clin Infect Dis.* 2002; 35:e92–5. [PubMed: 12384852]
97. Pukrittayakamee S, Imwong M, Looareesuwan S, White NJ. Therapeutic responses to antimalarial and antibacterial drugs in *vivax* malaria. *Acta Trop.* 2004; 89:351–6. [PubMed: 14744561]
98. Hasugian AR, Purba HLE, Kenangalem E, Wuwung M, Ebsworth EP, Maristela R, Penttinen P, Laihad F, Anstey NM, Tjitra E, Price RN. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and post treatment prophylaxis against multi-drug resistant *P. falciparum* and *P. vivax*. *Clin Infect Dis.* 2007 In Press.
99. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ. Effects of artesunate-mefloquine combination on incidence of *Plasmodium falciparum* malaria and mefloquine resistance in western Thailand: a prospective study. *Lancet.* 2000; 356:297–302. [PubMed: 11071185]
100. Baird JK. Resurgent malaria at the millennium: control strategies in crisis. *Drugs.* 2000; 59:719–43. [PubMed: 10804031]

Figure 1.

Published reports of treatment failure following chloroquine monotherapy (25mg base/kg up to 1.55g over three days) for *P. vivax* infections. Large white stars = clinical trials of chloroquine monotherapy with >10% recurrence rate by day 28; small black stars = case series with <5 recurrences before day 28 (with or without chloroquine plasma drug levels); black circles = clinical trials after 2000, with no recurrences by day 28.

Table 1

Estimates population at risk of *P. vivax* and number of clinical cases per year (in million)

		Population at Risk of <i>P. vivax</i> Infection (Millions)		Number of <i>P. vivax</i> Infections per year (millions)	
	WHO Regional Offices	Mendis et al 2	Guerra et al 3	Mendis et al 2	Hay et al 4 *
Africa	AFRO	550	50	6-15	-
America	AMRO	87.7	78	11.1	10 - 28
East Mediterranean	EMRO	64.6	211	11.7	11 - 34
Europe	EURO	-	20	-	1.4 - 4.2
Central Asia		8.5	-	0.17	-
Sea East Asia	SEARO	1,284	1,347	42.1	90 - 248
Western Pacific	WPRO		890		20 - 77
Total		1,995	2,596	71-80	132 - 391

* Adapted from estimates of non-falciparum malaria, assuming that *P. vivax* constitutes the 90% of these infections